Novan appoints CFO, chief commercial officer, with focus on acne treatment

Novan Therapeutics announced the appointments of two new executives with backgrounds in the dermatology industry.

Richard Peterson has been hired as chief financial officer and Brian Johnson as chief commercial officer, according to a press release. Peterson’s responsibilities will include the company’s financial operations, investor relations and other corporate functions, while Johnson will lead Novan’s commercialization efforts including sales, marketing and managed care for the company’s dermatology products, the release reported.

Both men discussed Novan’s SB204, its topical nitric oxide-based candidate for treating acne in the release.

“Novan’s success with SB204 has demonstrated the potential of a platform technology that promises to bring sustainable innovation into dermatology as we aggressively expand the pipeline into other indications,” Peterson stated in the release.

Peterson most recently served as executive vice president, chief financial officer and treasurer for Medicis Pharmaceutical Corp., where he had a nearly 20-year career, according to the release.

“It is rare when you are given the opportunity to build something special from the ground up,” Johnson stated in the release. “I am thrilled to be joining the Novan team as we turn the corner towards commercialization of SB204 for the treatment of acne and look forward to helping to create a preeminent dermatology company in the United States.”

Johnson has held marketing and sales leadership roles at Ortho Pharmaceutical Corp., Medicis Pharmaceutical Corp. and Galderma Laboratories LLC, according to the release.

Reference: www.novantherapeutics.com

 

Novan Therapeutics announced the appointments of two new executives with backgrounds in the dermatology industry.

Richard Peterson has been hired as chief financial officer and Brian Johnson as chief commercial officer, according to a press release. Peterson’s responsibilities will include the company’s financial operations, investor relations and other corporate functions, while Johnson will lead Novan’s commercialization efforts including sales, marketing and managed care for the company’s dermatology products, the release reported.

Both men discussed Novan’s SB204, its topical nitric oxide-based candidate for treating acne in the release.

“Novan’s success with SB204 has demonstrated the potential of a platform technology that promises to bring sustainable innovation into dermatology as we aggressively expand the pipeline into other indications,” Peterson stated in the release.

Peterson most recently served as executive vice president, chief financial officer and treasurer for Medicis Pharmaceutical Corp., where he had a nearly 20-year career, according to the release.

“It is rare when you are given the opportunity to build something special from the ground up,” Johnson stated in the release. “I am thrilled to be joining the Novan team as we turn the corner towards commercialization of SB204 for the treatment of acne and look forward to helping to create a preeminent dermatology company in the United States.”

Johnson has held marketing and sales leadership roles at Ortho Pharmaceutical Corp., Medicis Pharmaceutical Corp. and Galderma Laboratories LLC, according to the release.

Reference: www.novantherapeutics.com